SCHEMBL2367293

SCHEMBL2367293

NS(=O)(=O)c1ccc(S(=O)(=O)Cl)cc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA2 P00918 15/20 0.64
CA9 Q16790 13/20 0.64
CA1 P00915 13/20 0.64
CA12 O43570 12/20 0.64
CA5A P35218 8/20 0.64
CA7 P43166 8/20 0.64
CA5B Q9Y2D0 8/20 0.64
CA6 P23280 6/20 0.64
CA4 P22748 6/20 0.64
CA14 Q9ULX7 6/20 0.64
CA13 Q8N1Q1 3/20 0.64
CA3 P07451 3/20 0.64
TDP1 Q9NUW8 2/20 0.59
USP2 O75604 1/20 0.59
TSHR P16473 1/20 0.59
AGO2 Q9UKV8 1/20 0.59
ALDH1A1 P00352 2/20 0.55
HSD17B10 Q99714 1/20 0.55
PLA2G7 Q13093 1/20 0.55
HTT P42858 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
P-Toluenesulfonamide SCHEMBL28034266 0.89 CA2 (0.78) CA2CA9CA1CA12CA5A
SCHEMBL202948 0.85 CA2 (0.81) CA2CA9CA1CA12CA5A
SCHEMBL651902 0.85 ALDH1A1 (0.71) CA2CA9CA1CA12CA5A
Sulfanilamide SCHEMBL29080914 0.79 CA2 (0.85) CA2CA9CA1CA12CA5A
P-Chlorobenzenesulfonamide SCHEMBL196556 0.78 CA2 (1.00) CA2CA9CA1CA12CA5A
SCHEMBL759946 0.78 TSHR (0.62) CA2CA9CA1CA12CA5A
P-Chlorobenzenesulfonamide SCHEMBL31527679 0.78 CA2 (1.00) CA2CA9CA1CA12CA5A
SCHEMBL10493509 0.77 CA2 (0.68) CA2CA9CA1CA12CA5A
SCHEMBL9539098 0.77 ALDH1A1 (0.60) TDP1TSHRALDH1A1HSD17B10
SCHEMBL150162 0.77 ALDH1A1 (0.60) CA2CA9CA1CA12CA14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 154 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170279145-A1 MULTI-ACID POLYMERS FROM MULTIFUNCTIONAL AMINO ACIDS AND SULFONYL HALIDE PRECURSORS AND METHODS OF MAKING THE SAME NISSAN MOTOR CO., LTD. (JP) 2017-09-28 US claimed
EP-2142499-B1 Substituted sulphonamides, process for their preparation, pharmaceutical composition comprising thereof and their use for treating glaucoma UNIMED PHARMA SPOL SRO (SK) 2014-12-10 EP claimed
US-8193184-B2 Substituted sulphonamides, process for their preparation, pharmaceutical composition comprising thereof and their use Unimed Pharma, SPOL, S.R.O. (SK) 2012-06-05 US claimed
US-20100125076-A1 SUBSTITUTED SULPHONAMIDES, PROCESS FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITION COMPRISING THEREOF AND THEIR USE UNIMED PHARMA, SPOL. S R.O. (SK) 2010-05-20 US claimed
EP-2142499-A1 SUBSITUTED SULPHONAMIDES, PROCESS FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITION COMPRISING THEREOF AND THEIR USE Unimed Pharma, Spol. S R.O. (SK) 2010-01-13 EP claimed
WO-2008130332-A1 SUBSITUTED SULPHONAMIDES, PROCESS FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITION COMPRISING THEREOF AND THEIR USE UNIMED PHARMA, SPOL. S R.O. (SK) 2008-10-30 WO claimed
EP-3704090-B1 MODULATORS OF THE INTEGRATED STRESS PATHWAY CALICO LIFE SCIENCES LLC (US) 2026-05-27 EP disclosed
US-20260135164-A1 LITHIUM SECONDARY BATTERIES CAPABLE OF SELF-POISONING PROLOGIUM TECHNOLOGY CO., LTD. (TW) 2026-05-14 US disclosed
US-12606522-B2 Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives ORSOBIO, INC. (US) 2026-04-21 US disclosed
EP-4668392-A1 LITHIUM SECONDARY BATTERY CAPABLE OF SELF-POISONING Prologium Technology Co., Ltd. (TW) 2025-12-24 EP disclosed
EP-4668366-A1 LITHIUM SECONDARY BATTERY CAPABLE OF SELF-POISONING Prologium Technology Co., Ltd. (TW) 2025-12-24 EP disclosed
EP-3728194-B1 QUINOLINE SULFONAMIDE COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS OTAGO INNOVATION LTD (NZ) 2025-06-04 EP disclosed
CN-119998964-A Self-poisoning lithium secondary battery 辉能科技股份有限公司 2025-05-13 CN disclosed
EP-0673937-A1 BICYCLIC HETEROCYCLIC SULFONAMIDE AND SULFONIC ESTER DERIVATIVES Eisai Co., Ltd. (JP) 1995-09-27 EP disclosed
EP-0512304-A1 Silver halide color photographic elements containing a pyrazolo-triazole magenta coupler MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1992-11-11 EP disclosed
US-3984409-A CEREBRAL VASODILATORS PFIZER INC. (US) 1976-10-05 US disclosed
US-3957797-A CEREBRAL VASODILATORS PFIZER INC. (US) 1976-05-18 US disclosed
US-3932640-A CEREBRAL VASODILATORS PFIZER INC. (US) 1976-01-13 US disclosed
US-3932647-A CEREBRAL VASODILATORS PFIZER INC. (US) 1976-01-13 US disclosed
US-3932648-A CEREBRAL VASODILATORS PFIZER INC. (US) 1976-01-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260135164-A1 LITHIUM SECONDARY BATTERIES CAPABLE OF SELF-POISONING L3MBTL3, HAO2, LDHB CA2 14/4885CA9 28/4885CA1 12/4885
US-20100125076-A1 SUBSTITUTED SULPHONAMIDES, PROCESS FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITION COMPRISING THEREOF AND THEIR USE ARSA, SMS, SULT1E1 CA2 36/4885CA9 70/4885CA1 653/4885
US-12606522-B2 Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives NR3C2, NR5A1, SRD5A2 CA2 3086/4885CA9 1910/4885CA1 3778/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.